Exclusive Summary

• - Originator patents expired long ago; the 40 mg/mL oral suspension faces minimal patent barriers and has broad freedom to operate.
• - Targets large global pools in AIDS-related wasting and cancer cachexia—millions of patients with consistent demand in hospital and outpatient settings.
• - Recognized by guidelines (ASCO, NCCN/ESMO) for appetite/weight improvement and endocrine therapy, fitting oncology and HIV channels.
• - KR MFDS GMP plus multi-pharmacopoeia API (USP/EP/BP/KP) eases multi-country filing and tendering; TT enables local manufacturing advantage.
• - Compared with originator/improved formulations (Megace ES), the 40 mg/mL generic can deliver 60–90% cost savings, boosting access and reimbursement.

Asset Materials

Contact Us for Full Materials